Nurix Therapeutics(US:NRIX) 智通财经网·2025-12-09 02:37Core Insights - Nurix Therapeutics reported positive trial data for its drug bexobrutideg in treating blood cancers, leading to an 18.68% stock increase to $21.47 [1] Group 1: Clinical Trial Results - In a Phase 1a trial for R/R chronic lymphocytic leukemia (CLL), bexobrutideg achieved an objective response rate (ORR) of 83% among 47 evaluable patients, with a median progression-free survival of 22.1 months and a median duration of response of 20.1 months [1] - In a Phase 1 trial for patients with Waldenström's macroglobulinemia (WM), the ORR was 75% among 28 evaluable patients, with indications of durable and deepening responses over time [2] Group 2: Drug Development and Mechanism - Nurix Therapeutics focuses on discovering and developing oral small molecule therapies aimed at regulating cellular protein levels for cancer and immune diseases [2] - The company is developing targeted protein degraders for Bruton's tyrosine kinase (BTK) and inhibitors for Casitas B cell lymphoma proto-oncogene-B (CBL-B), which regulates T cell activation [2][3] - BTK inhibitors are crucial for treating various B cell blood cancers, but resistance to these inhibitors highlights the need for alternative strategies, such as targeted protein degradation [3] Group 3: Analyst Ratings and Market Outlook - Investment bank Needham reiterated a "Buy" rating for Nurix Therapeutics with a target price of $26, expressing confidence in the company's market prospects [3] - Truist initiated a "Buy" rating with a target price of $30, while BTIG maintained a "Buy" rating with a target price of $27 [3] - The average target price from 17 analysts for Nurix Therapeutics is $27.18, with a high of $41 and a low of $15 [3]